Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Qilu Pharmaceutical Co., Ltd.

Clinicaltrial registered9 Nov 2026

Qilu Pharmaceutical Co., Ltd.

9 Nov 2026: Trial registered · A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
9 Nov 2026
Title
A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase
Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07926048
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Qilu Pharmaceutical Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Qilu Pharmaceutical Co., Ltd. in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.